Childhood non-Hodgkinâ€™s lymphoma in Cipto Mangunkusumo Hospital, Jakarta: Outcome of treatment 2000-2005
AbstractBackground Childhood non-Hodgkinâ€™s lymphoma (NHL) is the third
most common solid tumor in Cipto Mangunkusumo, Jakarta. Since
1992 there was no national report on the survival of children with
NHL. To continue our observation on the result of treatment of chil-
dren with NHL in our institution, we briefly report the outcome therapy
of children with NHL who were admitted to our hospital during 2000-
Objective All patients who were diagnosed as non-Burkitt type NHL
between January 2000-December 2005 were included in the study.
Data collected retrospectively from the Oncology Registration of
Hematology-Oncology Division, Department of Child Health, Cipto
Mangunkusumo Hospital, including age, sex, primary site of tumor,
histopathology type, staging, treatment response, and outcome.
Results A total of 24 patients were available. Male:female ratio
was 1.8:1. The age range was from 9 months to 11 years (median
6 years). The histological type consisted of LL (3) and non-LL (11).
Ten out of 14 patients were diagnosed as advanced stages (stages
III and IV), while the rest were in stage II. Primary tumor site in LL
type were the head and neck (1), mediastinum (1), and testis (1),
while the non-LL type patients had more varied site. Overall sur-
vival of NHL was 78.6%+4.7%.
Conclusion The overall survival of childhood NHL patients treated
with protocol in our institution is in the range of survival that had
achieved in other centers worldwide, even with advanced stage of
children. In: Pizzo PA, Poplack DG, editors. Principles
and practice of pediatric oncology. Lippincott Williams
& Wilkins; Philadelphia: 2002, p. 661-705.
2. Johnston JM. Non-Hodgkin lymphoma. Cited from
3. Djajadiman Gatot, Idham Amir. Childhood non-
Hodgkinâ€™s lymphoma in Cipto Mangunkusumo Hos-
pital Jakarta: The obstacles in treatment and fol-
low-up. Indonesian Journal of Pathology;1992:40-
4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-
Hermelink HK, Vardiman J, et al. World Health Orga-
nization classification of neoplastic diseases of the he-
matopoietic and lymphoid tissues: Report of the clini-
cal advisory committee meeting-Airlie House, Virginia,
November 1997. J Clin Oncol 1999;17:3835-49.
5. Link MP, Shuster JJ, Donaldson SS, Berard CW,
Murphy SB. Treatment of children and young adults
with early-stage non-Hodgkinâ€™s lymphoma. N Engl J
6. Advani S, Pai S, Adde M, Vaidya S, Vats T, Naresh K,
et al. Preliminary report of an intensified, short dura-
tion chemotherapy protocol for the treatment of pedi-
atric non-Hodgkinâ€™s lymphoma in India. Ann Oncol
7. Kobrinsky NL, Sposto R, Shah NR, Anderson JR,
DeLaat C,Morse M, et al. Outcomes of treatment of
children and adolescents with recurrent non-Hodgkinâ€™s
lymphoma and Hodgkinâ€™s disease with dexamethasone,
etoposide, cisplatin, cytarabine and L-Asparaginase,
maintenance chemotherapy and transplantation:
Childrenâ€™s Cancer Group Study CCG-5912. J Clin
8. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin
Lymphoma in childhood. NEJM 1996;334:1238-48.
9. Lagrange JL, Ramaioli A, Theodore C, Terrier-Lacombe
MJ, Beckendorf V, Biron P, et al. Non-Hodgkinâ€™s lym-
phoma of the testis: A retrospective study of 84 pa-
tients treated in the French anticancer centres. Ann
10. Murphy SB, Frizzera G, Evans AE. A Study of child-
hood non-Hodgkin lymphoma. Cancer 1975;36:2121-
11. Weinstein HJ, Cassady JR, Levey R. Long-term results of
the APO protocol (vincristine, doxorubicin/adriamycin
and prednisone) for treatment of mediastinal lymphoblas-
tic lymphoma. J Clin Oncol 1983;1:537-41.
12. Dahl GV, Rivera G, Pui CH, Mirro J, Ochs J,
Kalwinsky DK, et al. A novel treatment of childhood
lymphoblastic non-Hodgkinâ€™s lymphoma: Early and
intermittent use of teniposide plus cytarabine. Blood
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.